Are you Dr. Balcerzak?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 7 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3113 N 3 Bs And K Rd
Sunbury, OH 43074Phone+1 740-524-7191
Summary
- Dr. Stanley Balcerzak, MD is an oncologist in Sunbury, Ohio. He is currently licensed to practice medicine in Ohio and Pennsylvania.
Education & Training
- University of ChicagoResidency, Internal Medicine, 1956 - 1960
- UPMC Medical EducationInternship, Transitional Year, 1955 - 1956
- University of Maryland School of MedicineClass of 1955
Certifications & Licensure
- OH State Medical License 1967 - 2025
- PA State Medical License 1963 - 1976
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 439 citationsPhase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.Victor Sandor, Susan Bakke, Robert W. Robey, Min H. Kang, Mikhail V. Blagosklonny
Clinical Cancer Research. 2002-03-01 - 23 citationsPhase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated a...Stephen H. Petersdorf, Cathryn Rankin, David R. Head, Howard R. Terebelo, Cheryl L. Willman
American Journal of Hematology. 2007-12-01 - 308 citationsA randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Sou...James K. Weick, Kenneth J. Kopecky, Frederick R. Appelbaum, David R. Head, Laura Kingsbury
Blood. 1996-10-15
Grant Support
- Phase I Trials Of Anticancer AgentsNational Cancer Institute1999
- Phase II Clinical Trials ConsortiumNational Cancer Institute1997–1998
- Core--Ambulatory Oncology UnitNational Cancer Institute1985–1994